Apoptosis in multiple sclerosis

Cell and Tissue Research

Volumn 301, Issue 1, 2000, Pages 163-171

  Zipp, Frauke ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Autoimmune disease; CD95; Multiple sclerosis; T cell; Therapy

Indexed keywords

FAS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOREGULATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE ACTIVATION; TISSUE INJURY;

ANIMALIA;

EID: 0033926601     PISSN: 0302766X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004410000179     Document Type: Review

References (86)

1. Akassoglou K, Bauer J, Kassiotis G, Pasparakis M, Lassmann H, Kollias G, Probert L (1998) Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system transgenic mice. Am J Pathol 153:801-813
2. Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281:1305-1308
3. Bachmann R, Eugster HP, Frei K, Fontana A, Lassmann H (1999) Impairment of TNF-receptor-1 signaling but not fas signaling diminishes T-cell apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice. Am J Pathol 154:1417-1422
4. Bauer J, Bradl M, Hickey WF, Forss-Peter S, Breitschopf H, Linington C, Wekerle H, Lassmann H (1998) T-cell apoptosis in inflammatory brain lesions. Destruction of T cells does not depend on antigen recognition. Am J Pathol 153:715-724
5. Bechmann I, Mor G, Nilsen J, Eliza M, Nitsch R, Naftolin F (1999) FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia 27:62-74
6. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC (1995) A role for CD95 ligand in preventing graft rejection. Nature 377:630-632
7. Boise LH, Gonzales-Garcia M, Postema CEDL, Lindsten T, Turka LA, Mao X, Nunez G, Thomson CB (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597-608
8. Bonetti B, Raine CS (1997) Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann Neurol 42:74-84
9. Brück W, Schmied M, Suchanek G, Brück Y, Breitschopf H, Poser S, Piddlesden S, Lassmann H (1994) Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 35:65-73
10. Brück W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar HA, Lassmann H (1995) Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 38:788-796
11. Carrieri PB, Provitera V, Bruno R, Perella M, Tartaglia G, Busto A, Perrella O (1997) Possible role of transforming growth factor-β in relapsing-remitting multiple sclerosis. Neurol Res 19:599-600
12. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762
13. Ciusani E, Frigerio S, Gelati M, Corsini E, Dufour A, Nespolo A, La Mantia L, Milanese C, Massa G, Salmaggi A (1998) Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 82:5-12
14. Critchfield JM, Racke MK, Zuniga-Pflucker JC, Cannella B, Raine CS, Goverman J, Lenardo MJ (1994) T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263:1139-1143
15. D'Souza SD, Bonetti B, Balasingam V, Cashman NR, Barker PA, Troutt AB, Raine CS, Antel JP (1996) Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med 184:2361-2370
16. Dhein J, Walczak H, Bèumler C, Debatin KM, Krammer PH (1995) Autocrine T-cell suicide mediated by APO-1/ (Fas/CD95). Nature 373:438-441
17. Dowling P, Shang G, Raval S, Menonna J, Cook S, Husar W (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 184:1513-1518
18. Dowling P, Husar W, Menonna J, Donnenfeld H, Cook S, Sidhu M (1997) Cell death and birth in multiple sclerosis brain. J Neurol Sci 149:1-11
19. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB (1996) Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 335:1643-1649
20. Elliott EA, McFarland H, Nye SH, Cofiell R, Wilson TM, Wilkins JA, Squinto SP, Matis LA, Mueller JP (1996) Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. J Clin Invest 98:1602-1612
21. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363-14367
22. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middelton LA, Lin AY, Strober W, Lenardo MJ, Puck JM (1995) Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81:935-946
23. Gao Y, Herndon JM, Zhang H, Griffith TS, Ferguson TA (1998) Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis. J Exp Med 188:887-896
24. Gatenby PA, Irvine M (1994) The bcl-2 proto-oncogene is overexpressed in systemic lupus erythematosus. J Autoimmun 7:623-631
25. Gold R, Hartung HP, Lassmann H (1997) T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci 20:399-404
26. Golstein P (1997) Cell death: TRAIL and its receptors. Curr Biol 7:R750-R753
27. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189-1192
28. Hengartner M (1998) Death by crowd control. Science 281:1298-1299
29. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336
30. Hohlfeld R (1997) Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120:865-916
31. Hornung F, Zheng L, Lenardo MJ (1997) Maintenance of clonotypic specificity in CD95/Apo-1/Fas-mediated apoptosis of mature T lymphocytes. J Immunol 159:3816-3822
32. Inoue A, Koh C, Sakai T, Yamazaki M, Yanagisawa N, Usuku K, Osame M (1997) Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. J Neuroimmunol 75:141-146
33. Ishigami T, White CA, Pender MP (1998) Soluble antigen therapy induces apoptosis of autoreactive T cells preferentially in the target organ rather than in the peripheral lymphoid organs. Eur J Immunol 28:1626-1635
34. Kaser A, Deisenhammer F, Berger T, Tilg H (1999) Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients. Lancet 353:1413-1414
35. Krammer PH (1998) CD95(APO-1/Fas)-mediated apoptosis: live and let die. Adv Immunol 71:163-210
36. Kuhlmann T, Lucchinetti CF, Zettl U, Brück W (1999) Bcl-2 expressing oligodendrocytes in multiple sclerosis lesions. Glia 28:34-39
37. Lassmann H, Brück W, Lucchinetti C, Rodriguez M (1997) Remyelination in multiple sclerosis. Mult Scler 3:133-136
38. Le Deist F, Emile JF, Rieux-Laucat LF, Benkerrou M, Roberts I, Brousse N, Fischer A (1996) Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet 348:719-723
39. Lenardo M, Chan FK, Hornung F, McFarland H, Siegel R, Wang J, Zheng L (1999) Mature T lymphocyte apoptosis - immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 17:221-253
40. Lucchinetti CF, Brück W, Moses R, Lassmann H (1996) Distinct patterns of multiple sclerosis pathology indicate heterogeneity in pathogenesis. Brain Pathol 6:259-274
41. Macchi B, Matteucci C, Nocentini U, Caltagirone C, Mastino A (1999) Impaired apoptosis in mitogen-stimulated lymphocytes of patients with multiple sclerosis. Neuroreport 10:399-402
42. Malipiero U, Frei K, Spanaus K-S, Agresti C, Lassmann H, Hahne M, Tschopp J, Eugster H-P, Fontana A (1997) Myelin oligodendrocyte glycoprotein-induced encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas-and Fas ligand-deficient lpr and gld mice. Eur J Immunol 27: 3151-3160
43. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, Ashkenazi A (1997) A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 7:1003-1006
44. Martin R, McFarland HF, McFarlin DE (1992) Immunological aspects of demyelinating diseases. Annu Rev Immunol 10:153-187
45. Martino G, Hartung HP (1999) Immunopathogenesis of multiple sclerosis: the role of T cells. Curr Opin Immunol 12:309-321
46. Mehrian R, Quismorio FPJ, Strassmann G, Stimmler MM, Horwitz DA, Kitridou RC, Gauderman WJ, Morrison J, Brautbar C, Jacob CO (1998) Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 41:596-602
47. Moalem G, Monsonego A, Shani Y, Cohen IR, Schwartz M (1999) Differential T cell response in central and peripheral nerve injury: connection with immune privilege. FASEB J 13:1207-1217
48. Nagata S, Golstein P (1995) The Fas death factor. Science 267: 1449-1456
49. Nagatani T, Okazawa H, Kambara T, Satoh K, Nishiyama T, Tokura H, Yamada R, Nakajima H (1998) Effect of natural interferon-beta on the growth of melanoma cell lines. Melanoma Res 8:295-299
50. Olsson T, Sun J, Hillert J, Hojeberg B, Ekre HP, Andersson G, Olerup O, Link H (1992) Increased numbers of T cells recognizing multiple myelin basic protein epitopes in multiple sclerosis. Eur J Immunol 22:1083-1087
51. Oltvai ZN, Milliman ZL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619
52. Pan G, Ni J, Wei Y, Yu G, Gentz R, Dixit VM (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-818
53. Pilling D, Akbar AN, Girdlestone J, Orteu CH, Borthwick NJ, Amft N, Scheel TD, Buckley CD, Salmon M (1999) Interferon-beta mediates stromal cell rescue of T cells from apoptosis. Eur J Immunol 29:1041-1050
54. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699-703
55. Reed JC (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1-6
56. Rep MH, Schrijver HM, van LT, Hintzen RQ, Roos MT, Ader HJ, Polman CH, van LR (1999) Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients. J Neuroimmunol 96:92-100
57. Rieux-Laucat LF, Le Deist DF, Hivroz C, Roberts IA, Debatin KM, Fischer A, de VJ (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347-1349
58. Roth W, Wagenknecht B, Dichgans J, Weller M (1998) Interferon-alpha enhances CD95L-induced apoptosis of human malignant glioma cells. J Neuroimmunol 87:121-129
59. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, French L, Van Meir EG, de Tribolet N, Tschopp J, Dietrich PY (1997) Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 99: 1173-1178
60. Sabelko KA, Kelly KA, Nahm MH, Cross AH, Russell JH (1997) Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J Immunol 159:3096-3099
61. Sabelko-Downes DK, Cross AH, Russell JH (1999) Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J Exp Med 189:1195-1205
62. Schmidt S, Linington C, Zipp F, Sotigui S, de Waal Malefyt R, Weckerle H, Hohlfeld R (1997) Multiple sclerosis: comparison of the human T cell response to S100β and MBP reveals parallels to rat experimental autoimmune panencephalitis (EAP). Brain 120:1437-1445
63. Schmied M, Breitschopf H, Gold R, Zischler H, Rothe G, Wekerle H, Lassmann H (1993) Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis: evidence for programmed cell death as a mechanism to control inflammation in the brain. Am J Pathol 143:446-452
64. Selleri C, Sato T, Del Vecchio L, Luciano L, Barrett AJ, Rotoli B, Young NS, Maciejewski JP (1997) Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-α in chronic myelogenous leukemia. Blood 89:957-964
65. Selmaj K, Raine C, Farooq M, Morton W, Brosnan C (1991) Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. J Immunol 147:1522-1529
66. Sheridan JP, Marsters S, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-821
67. Suvannavejh GC, Dal Canto MC, Matis LA, Miller SD (2000) Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 105: 223-231
68. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis [see comments]. N Engl J Med 338:278-285
69. van Parijs L, Peterson DA, Abbas AK (1998) The Fas/Fas ligand pathway and bcl-2 regulate T cell responses to model self and foreign antigens. Immunity 8:265-274
70. Waldner H, Sobel RA, Howard E, Kuchroo VK (1997) Fas-and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J Immunol 159:3100-3103
71. Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C (1994) Animal models. Ann Neurol 36:S47-S53
72. Weller M, Constam DB, Malipiero U, Fontana A (1994) Transforming growth factor-β2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. Eur J Immunol 24:1293-1300
73. Wendung U, Aktas O, Schmierer K, Zschenderlein R, Zipp F (2000) Partial synergy of bisindolylmaleimide with apoptotic stimulus in antigen-specific T cells - implications for multiple sclerosis. J Neuroimmunol 103:69-75
74. White CA, McCombe PA, Pender MP (1998) The roles of Fas, Fas ligand and Bcl-2 in T cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis. J Neuroimmunol 82:47-55
75. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682
76. Yang E, Korsmeyer SJ (1997) Molecular thanatopsis: a discourse on the bcl-2 family and cell death. Blood 88:386-401
77. Zang YCQ, Kozovska MM, Hong J, Li S, Mann S, Killian JM, Rivera VM, Zhang JZ (1999) Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur J Immunol 29:1692-1700
78. Zettl UK, Kuhlmann T, Brück W (1998) Bcl-2 expressing T lymphocytes in multiple sclerosis lesions. Neuropathol Appl Neurobiol 24:202-208
79. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA (1994) Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 179:973-984
80. Zhou T, Song L, Yang P, Wang Z, Lui D, Jope RS (1999) Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases. Nat Med 5:42-48
81. Zipp F, Martin R, Lichtenfels R, Roth W, Dichgans J, Krammer PH, Weller M (1997) Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by recombinant CD95 ligand. J Immunol 159:2108-2115
82. Zipp F, Faber E, Sommer N, Müller C, Dichgans J, Krammer PH, Martin R, Weller M (1998a) CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis. No differences from normal individuals and no relation to HLA-DR2. J Neuroimmunol 81:168-172
83. Zipp F, Otzelberger K, Dichgans J, Martin R, Weller M (1998b) Serum CD95 of multiple sclerosis patients protects from CD95-mediated apoptosis. J Neuroimmunol 86:151-154
84. Zipp F, Weller M, Calabresi PA, Frank JA, Bash CN, Dichgans J, McFarland H, Martin R (1998c) Increased serum levels of soluble CD95 (APO1/Fas) in relapsing remitting multiple sclerosis. Ann Neurol 43:116-120
85. Zipp F, Krammer PH, Weller M (1999) Immune (dys)regulation in multiple sclerosis: role of the CD95/CD95 ligand system. Immunol Today 20:550-554
86. Zipp F, Beyer M, Gelderblom H, Wernet D, Zschenderlein R, Weller M (2000) No induction of apoptosis by IFN-beta in human antigen-specific T cells. Neurology 54:524-526